These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33309946)

  • 61. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch G; Brannath W; Brückner M; Kieser M
    Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Halabi S
    Lifetime Data Anal; 2020 Apr; 26(2):266-291. PubMed ID: 30980317
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Repeated significance tests on accumulating survival data.
    Skovlund E
    J Clin Epidemiol; 1999 Nov; 52(11):1083-8. PubMed ID: 10527002
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization.
    Peterson RL; Vock DM; Babiker A; Powers JH; Hunsberger S; Angus B; Paez A; Neaton JD;
    Contemp Clin Trials Commun; 2019 Sep; 15():100401. PubMed ID: 31312748
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Validity of the Hochberg procedure revisited for clinical trial applications.
    Huque MF
    Stat Med; 2016 Jan; 35(1):5-20. PubMed ID: 26278421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peritoneal antiseptic irrigation to prevent surgical site infection after laparotomy for hepatobiliary or gastrointestinal surgery (PAISI)-protocol for a randomized controlled study.
    Mueller T; Kehl V; Egert-Schwender S; Friess H; Novotny A; Reim D
    Trials; 2022 Dec; 23(1):1029. PubMed ID: 36539884
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The fallback procedure for evaluating a single family of hypotheses.
    Wiens BL; Dmitrienko A
    J Biopharm Stat; 2005; 15(6):929-42. PubMed ID: 16279352
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A parametric multiple test procedure to adaptive group-sequential trials allowing for mid-term modifications.
    Jin M
    Contemp Clin Trials; 2020 Mar; 90():105955. PubMed ID: 32028024
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
    Tan M; Xiong X
    Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimizing the order of hypotheses in serial testing of multiple endpoints in clinical trials.
    Zhang Z; Wang C; Troendle JF
    Stat Med; 2015 Apr; 34(9):1467-82. PubMed ID: 25620627
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Incorporation of sequential trials into a fixed effects meta-analysis.
    Todd S
    Stat Med; 1997 Dec; 16(24):2915-25. PubMed ID: 9483723
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A rank test for bivariate time-to-event outcomes when one event is a surrogate.
    Shaw PA; Fay MP
    Stat Med; 2016 Aug; 35(19):3413-23. PubMed ID: 27059817
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Two-stage clinical trial stopping rules.
    Elashoff JD; Reedy TJ
    Biometrics; 1984 Sep; 40(3):791-5. PubMed ID: 6518247
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis.
    Chen YH; DeMets DL; Lan KK
    Control Clin Trials; 2003 Feb; 24(1):16-27. PubMed ID: 12559639
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
    Pilz LR; Manegold C; Schmid-Bindert G
    Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.